enoxaparin + placebo (Bayer)

This entry refers to the control arm treatment regimen used in the MAGELLAN Phase 3 clinical trial, which compared extended-duration rivaroxaban to standard-duration enoxaparin for the prevention of venous thromboembolism (VTE) in acutely ill medical patients. The regimen consists of active subcutaneous enoxaparin (40 mg once daily) administered for 10±4 days, followed by an oral placebo for the remainder of a 35±4 day period. Enoxaparin is a low-molecular-weight heparin (LMWH) that exerts its anticoagulant effect by accelerating the activity of antithrombin III, which primarily inhibits coagulation factors Xa and IIa (thrombin). This specific sequential administration was designed to maintain the blind against the experimental arm (rivaroxaban) while providing the standard-of-care duration for enoxaparin in hospitalized patients.

Brand names

Lovenox

Other names

enoxaparin placebo-Bayer-venous thromboembolismMAGELLAN control armstandard-duration enoxaparin regimen